• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:杨建苗,许东航,李范珠.克服肿瘤多药耐药的药物共递送纳米载体的设计及研究新方向[J].中国现代应用药学,2020,37(6):750-754.
YANG Jianmiao,XU Donghang,LI Fanzhu.Advance in the Design and Development of Nanocarrier-mediated Co-delivery for Overcoming Multidrug-resistant Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(6):750-754.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2455次   下载 2025 本文二维码信息
码上扫一扫!
分享到: 微信 更多
克服肿瘤多药耐药的药物共递送纳米载体的设计及研究新方向
杨建苗1,2, 许东航3, 李范珠2
1.台州恩泽医疗中心(集团)浙江省台州医院, 浙江 台州 317000;2.浙江中医药大学, 杭州 310053;3.浙江大学医学院附属第二医院, 杭州 310009
摘要:
多药耐药(multidrug resistance,MDR)是肿瘤治疗成功的主要障碍,药物共递送纳米载体因其肿瘤靶向、控制释放、一致的药动学曲线而被认为是克服MDR的有效策略。本综述总结了当前克服MDR的药物共递送纳米载体的设计思路,并分析了具有前景的研究方向,包括精确药物负载纳米载体、呈时序释放的纳米载体和对肿瘤微环境设计纳米载体,这些新兴策略为临床肿瘤治疗提供了新颖且更好的定制组合方案。
关键词:  纳米技术  药物共递送纳米载体  多药耐药  肿瘤治疗
DOI:10.13748/j.cnki.issn1007-7693.2020.06.024
分类号:
基金项目:浙江省自然科学基金资助项目(LY18H300004,LY15H300001);台州市科技计划项目(1801ky04)
Advance in the Design and Development of Nanocarrier-mediated Co-delivery for Overcoming Multidrug-resistant Cancer
YANG Jianmiao1,2, XU Donghang3, LI Fanzhu2
1.Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center(Group), Taizhou 317000, China;2.Zhejiang Chinese Medical University, Hangzhou 310053, China;3.Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
Abstract:
Multidrug resistance(MDR) is a major obstacle to successful cancer treatment. Nanocarrier-mediated co-delivery is an effective strategy for overcoming MDR, which possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. In this review, a summary of various design strategy of nanocarrier-mediated co-delivery was presented, and highlighted the recent advances in nanocarrier-mediated co-delivery against cancer drug resistance, including co-encapsulation of drugs with ratiometric control over drug loading, temporal sequencing on drug release, and tumor microenvironment. These emerging strategies promise novel and better tailored combinatorial regimens for clinical cancer treatment.
Key words:  nanotechnology  nanocarrier-mediated co-delivery  multidrug resistance  cancer therapy
扫一扫关注本刊微信